This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lorch, A. Articles by Rick, O. Search for Related Content PubMed PubMed Citation Articles by Lorch, A. Articles by Rick, O. Social Bookmarking                            What's this?

Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group

Anja Lorch, Christian Kollmannsberger, Joerg Thomas Hartmann, Bernd Metzner, Ingo G.H. Schmidt-Wolf, Wolfgang E. Berdel, Florian Weissinger, Jan Schleicher, Gerlinde Egerer, Antje Haas, Rebekka Schirren, Jörg Beyer, Carsten Bokemeyer, Oliver Rick

From the Departments of Hematology and Oncology, Universitätsklinikum Giessen und Marburg GmbH, Marburg; Universitätsklinikum, Tübingen; Klinikum Oldenburg, Oldenburg; Universitätsklinikum, Bonn; Universitätsklinikum, Münster; Universitätsklinikum, Würzburg; Katharinenhospital, Stuttgart; Universitätsklinikum, Heidelberg; Klinikum Ernst-von-Bergmann, Potsdam; Vivantes Krankenhaus Am Urban, Berlin; Universitätskrankenhaus Eppendorf, Hamburg; Klinik Reinhardshöhe, Bad-Wildungen, Germany; and British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Address reprint requests to J. Beyer, MD, Direktor Klinik für Hämatologie und Onkologie, Vivantes Klinikum Am Urban, Dieffenbachstrasse 1, 10967 Berlin, Germany; e-mail joerg.beyer{at}vivantes.de

Purpose To compare single versus sequential high-dose chemotherapy (HDCT) as first or subsequent salvage treatment in patients with relapsed or refractory germ cell tumors (GCTs).

Patients and Methods Between November 1999 and November 2004, 230 patients were planned to be recruited in a prospective, randomized, multicenter trial comparing one cycle of cisplatin 100 mg/m², etoposide 375 mg/m², and ifosfamide 6 g/m² (VIP) plus three cycles of high-dose carboplatin 1,500 mg/m² and etoposide 1,500 mg/m² (CE; arm A) versus three cycles of VIP plus one cycle of high-dose carboplatin 2,200 mg/m², etoposide 1,800 mg/m², and cyclophosphamide 6,400 mg/m² (CEC; arm B).

Results The study was stopped prematurely after recruitment of 216 patients as a result of excess treatment-related mortality in arm B. One hundred eleven (51%) of 216 patients were randomly assigned to sequential HDCT, and 105 (47%) of 216 patients were randomly assigned to single HDCT. Five (2%) of 216 patients had to be excluded because of non-GCT histologies at review. With a median follow-up time of 36 months, 109 (52%) of 211 patients were alive, and 91 (43%) of 211 patients were progression free. At 1 year, event-free, progression-free, and overall survival rates were 40%, 53%, and 80%, respectively, in arm A compared with 37%, 49%, and 61%, respectively, in arm B (P > .05 for all comparisons). Treatment-related deaths, mainly as a result of sepsis and cardiac toxicity, were less frequent in arm A (four of 108 patients, 4%) compared with arm B (16 of 103 patients, 16%; P < .01).

Conclusion We found no difference in survival probabilities between single HDCT using CE and sequential HDCT using CEC. Sequential HDCT was better tolerated and resulted in fewer treatment-related deaths.

C.B., O.R., and J.B. equally contributed to the conception and design of the study, the provision of patients, and the data interpretation and analysis on behalf of the German Testicular Cancer Study Group.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Hentrich, X. Schiel, A. Niedermeier, L. Lutz, R. Rupec, C. Stief, J. Bogner, M. Karthaus, and A. Gerl Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor Ann. Onc., November 1, 2009; 20(11): 1900 - 1901. [Full Text] [PDF]

				K. I. Pritchard Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 959 - 962. [Full Text] [PDF]

				C. Theodore, C. Chevreau, Y. Yataqhene, K. Fizazi, J. -P. Delord, J. -P. Lotz, L. Geoffrois, P. Kerbrat, V. Bui, and A. Flechon A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors Ann. Onc., August 1, 2008; 19(8): 1465 - 1469. [Abstract] [Full Text] [PDF]

				J. Shamash, J. Stebbing, T. Powles, A. Lorch, J. Beyer, C. Bokemeyer, V. Kondagunta, M. D. Galsky, G. Sonpavde, U. De Giorgi, et al. Germ-Cell Tumors N. Engl. J. Med., October 25, 2007; 357(17): 1771 - 1774. [Full Text] [PDF]

				What Is the Optimal Salvage Therapy for Patients with Relapsed Germ-Cell Tumors? Journal Watch Oncology and Hematology, July 25, 2007; 2007(725): 2 - 2. [Full Text]